S. Bonvalot, A. Desai, S. Coppola, L. Péchoux, C. Terrier et al., The treatment of desmoid tumors: a stepwise clinical approach, Annals of Oncology, vol.23, issue.suppl 10, pp.158-166
DOI : 10.1093/annonc/mds298

M. Von-mehren, R. Benjamin, M. Bui, E. Casper, E. Conrad et al., Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines, J Natl Compr Canc Netw, vol.10, pp.951-960, 2012.

D. Garbay, L. Cesne, A. Penel, N. Chevreau, C. Marec-berard et al., Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG), Annals of Oncology, vol.23, issue.1, pp.182-186, 2012.
DOI : 10.1093/annonc/mdr051

M. Gega, H. Yanagi, R. Yoshikawa, M. Noda, H. Ikeuchi et al., Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis, Journal of Clinical Oncology, vol.24, issue.1, pp.102-105, 2006.
DOI : 10.1200/JCO.2005.02.1923

A. Hansmann, C. Adolph, T. Vogel, A. Unger, and G. Moeslein, High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors, Cancer, vol.27, issue.3, pp.612-620, 2004.
DOI : 10.1002/cncr.11937

M. Gounder, R. Lefkowitz, M. Keohan, D. Adamo, D. Hameed et al., Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis, Clinical Cancer Research, vol.17, issue.12, pp.4082-4090, 2011.
DOI : 10.1158/1078-0432.CCR-10-3322

N. Penel, L. Cesne, A. Bui, B. Perol, D. Brain et al., Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up, Annals of Oncology, vol.22, issue.2, pp.452-457, 2011.
DOI : 10.1093/annonc/mdq341

R. Chugh, J. Wathen, S. Patel, R. Maki, P. Meyers et al., Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial, Clinical Cancer Research, vol.16, issue.19, pp.4884-4891, 2010.
DOI : 10.1158/1078-0432.CCR-10-1177

M. Heinrich, C. Corless, G. Demetri, C. Blanke, M. Von-mehren et al., Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor, Journal of Clinical Oncology, vol.21, issue.23, pp.4342-4349, 2003.
DOI : 10.1200/JCO.2003.04.190

J. Guo, L. Si, Y. Kong, K. Flaherty, X. Xu et al., Mutation or Amplification, Journal of Clinical Oncology, vol.29, issue.21, pp.2904-2909, 2011.
DOI : 10.1200/JCO.2010.33.9275

L. Schirosi, N. Nannini, D. Nicoli, A. Cavazza, R. Valli et al., Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors, Annals of Oncology, vol.23, issue.9, pp.2409-2414, 2012.
DOI : 10.1093/annonc/mdr626

A. Gonçalves, G. Monges, Y. Yang, F. Palmerini, P. Dubreuil et al., Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis, JNCI Journal of the National Cancer Institute, vol.98, issue.8, pp.562-563, 2006.
DOI : 10.1093/jnci/djj137

J. Seinfeld, B. Kleinschmidt-demasters, S. Tayal, and K. Lillehei, mutational status, Journal of Neurosurgery, vol.104, issue.5, pp.749-756, 2006.
DOI : 10.3171/jns.2006.104.5.749

A. Dufresne, F. Bertucci, N. Penel, L. Cesne, A. Bui et al., Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis, British Journal of Cancer, vol.103, issue.4, pp.482-485, 2010.
DOI : 10.1093/jnci/djj417

S. Salas, A. Dufresne, B. Bui, J. Blay, P. Terrier et al., Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation, Journal of Clinical Oncology, vol.29, issue.26, pp.3553-3558, 2011.
DOI : 10.1200/JCO.2010.33.5489

A. Crago, B. Denton, S. Salas, A. Dufresne, J. Mezhir et al., A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis, Annals of Surgery, vol.258, issue.2, pp.347-353, 2013.
DOI : 10.1097/SLA.0b013e31828c8a30

V. Kotoula, E. Charalambous, B. Biesmans, A. Malousi, E. Vrettou et al., Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics, PLoS ONE, vol.26, issue.11, pp.1471-2407632, 2009.
DOI : 10.1371/journal.pone.0007746.t005

S. Bustin, J. Beaulieu, J. Huggett, R. Jaggi, F. Kibenge et al., MIQE pr??cis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments, BMC Molecular Biology, vol.11, issue.1, p.74, 2010.
DOI : 10.1186/1471-2199-11-74

A. Didelot, L. Corre, D. Luscan, A. Cazes, A. Pallier et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples, Experimental and Molecular Pathology, vol.92, issue.3, pp.275-280, 2012.
DOI : 10.1016/j.yexmp.2012.03.001

J. Kurtz, I. Asmane, A. Voegeli, A. Neuville, A. Dufresne et al., A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis, Sarcoma, vol.25, issue.18, supplement, p.458156, 2010.
DOI : 10.1007/s00280-009-1010-0

R. Foster, E. Byrnes, C. Meldrum, R. Griffith, G. Ross et al., Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT, British Journal of Dermatology, vol.22, pp.1160-1169, 2008.
DOI : 10.1111/j.1365-2133.2008.08827.x

J. Rocha, L. Duarte, M. Marques, H. Torres, F. Tavares et al., Association of adult mastocytosis with M541L in the transmembrane domain of KIT, Journal of the European Academy of Dermatology and Venereology, vol.32, pp.1118-1119, 2010.
DOI : 10.1111/j.1468-3083.2010.03599.x

K. Inokuchi, H. Yamaguchi, M. Tarusawa, M. Futaki, H. Hanawa et al., Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia ??? potential clinical significance, Leukemia, vol.16, issue.2, pp.170-177, 2002.
DOI : 10.1038/sj.leu.2402341

S. Krüger, M. Emig, P. Lohse, G. Ehninger, A. Hochhaus et al., The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians, Leukemia, vol.12, issue.2, pp.354-355, 2006.
DOI : 10.1038/sj.leu.2404038

F. Grabellus, K. Worm, S. Sheu, W. Siffert, K. Schmid et al., The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population, Journal of Clinical Pathology, vol.64, issue.11, pp.1021-1024, 2011.
DOI : 10.1136/jcp.2011.090498

. Dufresne, Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology, BMC Cancer, vol.64, issue.Suppl 10, p.632, 2014.
DOI : 10.1136/jcp.2011.090498

URL : https://hal.archives-ouvertes.fr/inserm-01097447